### Liquid biopsies, biomarkers, and novel therapies in renal tumours

Poster Session 19

**Saturday 10 July**  
**13:00 - 14:00**

<table>
<thead>
<tr>
<th>Location</th>
<th>Virtual Room 8</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairs</td>
<td>To be confirmed</td>
</tr>
<tr>
<td></td>
<td>H-P. Marti, Bergen (NO)</td>
</tr>
</tbody>
</table>

We encourage you to view the abstracts prior to the session:

- On 8 June abstract bodies will be available for EAU members in the EAU21 Resource Centre.
- On 1 July abstract bodies and 5-minute explanatory presentations will be available for all delegates on the EAU21 Congress platform.

The presentations in this poster session (1 minute in length) are divided into groups, followed by discussion time to address questions from the audience and the chairpersons.

**13:00 - 13:01**  
**Introduction**

**13:01 - 13:11**  
**Liquid biopsy, exosomes**

**P0533**  
Kidney cancer urine marker  
B. Köditz, Köln (DE)

**P0534**  
Role of exosomal antitumor microRNA-1 in renal cell carcinoma

**P0535**  
Expression of PD-L1 on extracellular vesicles in renal cell carcinoma cell lines and patient samples  
P. Zeuschner, Homburg (DE)

**P0536**  
Tumor specific exosome-based liquid biopsy biomarkers for kidney cancer  
R.C. Zieren, Baltimore (US)

**P0537**  
Organ-specific uptake of extracellular vesicles secreted by urological cancer cells  
J. Linxweiler, Homburg/ saar (DE)

**13:06 - 13:11**  
**Discussion**

**13:11 - 13:34**  
**Novel biomarkers**

**P0538**  
N6-Methyladenosine (m6A) readers are dysregulated in renal cell carcinoma  
J. Ellinger, Bonn (DE)

**P0539**  
Ubiquitin modification patterns of clear cell renal cell carcinoma and the ubiquitin score to aid immunotherapy and targeted therapy  
P. Zhou, Wuhan (CN)

**P0540**  
Clinicopathological and prognostic significance of TFE3 in papillary renal carcinoma  
T. Takamatsu, Fukuoka (JP)

**P0541**  
Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with renal cell carcinoma  
W. Kong, Shanghai (CN)

**P0542**  
Comprehensive molecular characterization of renal cell carcinoma in the Chinese population  
W. Kong, Shanghai (CN)

**P0543**  
A multi-omics approach for kidney cancer biomarker discovery  
R.C. Zieren, Baltimore (US)
miR-92b-3p is a prognostic oncomiR that targets TSC1 in clear cell renal cell carcinoma

DNA Damage Repair (DDR) gene and VHL concurrent alterations in advanced clear cell Renal Cell Carcinoma (ccRCC) are association with good progression free survival with tyrosine kinase inhibitor therapy

W. Zhai, Shanghai (CN)

Development and validation of a nine redox related long noncoding RNA prognostic signature in renal clear cell carcinoma

Q-D. Xia, Wuhan (CN)

PDCD1 methylation predicts response to anti–PD-1 based immunotherapy in advanced and metastatic renal cell carcinoma

N. Klümper, Bonn (DE)

CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma

G. Tulchiner, Innsbruck (AT)

Transcriptome-based estimation of immune cell populations is prognostic for risk of relapse in localized renal cell carcinoma

E. Roussel, Brugge (BE)

Tryptophan 2,3-dioxygenase in tumor cells is associated with kynurenine accumulation and resistance to immunotherapy in renal cell carcinoma

M. Sumitomo, Aichi (JP)

Comprehensive molecular characterization of TFE3-translocation renal cell carcinoma

J. Chen, Chengdu (CN)

An in vitro comparison between Cabozantinib as first- and second-line agent in metastatic renal cell carcinoma

A. Zaccagnino, Homburg (DE)

KIBRA plays as tumour suppressor via phosphorylation of LATS-2 in conventional renal cell carcinoma tissues

K. Mitsunari, Nagasaki (JP)

Anti-mesothelin human CAR-T cells producing IL-7 and CCL19 enhance antitumor efficacy against solid cancer in orthotopic and PDX mouse models

S. Goto, Ube-shi (JP)

Successful therapy of experimental, orthotopic renal cell carcinoma with two different types of Axl inhibiting agents

T.J. Chen, Bergen (NO)

Combination of mAb cG250 with natural killer cells for RCC treatment

J.C. Oosterwijk-Wakka, Nijmegen (NL)

Cytotoxic T lymphocytes regenerated from iPS cells have therapeutic efficacy in a patient-derived xenograft model of renal cell carcinoma

S. Kashima, Akita (JP)

Deconstruction of metastatic tumor microenvironment reveals a metastatic immunosignature predictive of prognosis and treatment response in ccRCC

Y. Xiong, Shang Hai (CN)

Typical prognostic immune subtypes of clear cell renal cell carcinoma defined by the unique tumor immune microenvironment

W-H. Xu, Shanghai (CN)
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P0560</td>
<td>Inhibition of autophagy as a therapeutic concept in renal cell carcinoma</td>
<td>V. Stuehler, Tuebingen (DE)</td>
</tr>
<tr>
<td>P0561</td>
<td>Efficacy and safety of anlotinib in metastatic renal cell carcinoma: A single-center retrospective study</td>
<td>H. Zhu, Xuzhou (CN)</td>
</tr>
<tr>
<td>P0562</td>
<td>Comprehensive genome-wide profiles reveals prognosis-related alternative splicing events landscape and identifies DDX21 as novel signature in adrenocortical carcinoma</td>
<td>W-H. Xu, Shanghai (CN)</td>
</tr>
</tbody>
</table>

13:46 - 13:55 Discussion

13:55 - 14:00 Expert summary
To be confirmed